Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models

PI3K pathway activation is frequently observed in triple negative breast cancer (TNBC). However, single agent PI3K inhibitors have shown limited anti-tumor activity. To investigate biomarkers of response and resistance mechanisms, we tested 17 TNBC patient-derived xenograft (PDX) models representing...

Full description

Bibliographic Details
Main Authors: Zhanfang Guo, Tina Primeau, Jingqin Luo, Cynthia Zhang, Hua Sun, Jeremy Hoog, Feng Gao, Shixia Huang, Dean P. Edwards, Sherri R. Davies, Rebecca Aft, Li Ding, Matthew J. Ellis, Shunqiang Li, Cynthia X. Ma
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
biomarkers
PI3K inhibitor
BKM120
triple negative breast cancer
patient-derived xenograft
Online Access:https://www.mdpi.com/2072-6694/12/12/3857

Internet

https://www.mdpi.com/2072-6694/12/12/3857

Similar Items